Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BIO Notebook Day 2: Levin Scolds Industry For Squandering Proceeds From US Tax Reform

Executive Summary

Former Teva and current Ovid CEO Jeremy Levin says pharma should use tax reform gains for business development, not share buybacks. Also, Patient-focused drug development (PFDD) is about more than just getting new drugs approved, an advocate says, while FDA previews coming guidance on PFDD. And, Alnylam’s CEO reflects on what it took financially to get RNAi to the threshold of its first product approval.

Advertisement

Related Content

Levin Calls Takeda/Shire Merger ‘Inspired,’ Says Entire Value Chain Must Address Pricing Issue
BIO Notebook Day 3: ARM Launches Foundation To Educate Public About Gene And Cell Therapies
BIO Notebook Day 3: ARM Launches Foundation To Educate Public About Gene And Cell Therapies
Q1 Was Slow For Deals, But That Could Change With One Big Transaction – PwC
Alnylam Set For Transformation As Patisiran Nears Market With Data Upgrade
How Is Pharma Spending Tax Savings? Not On Drug Pricing, Sen. Booker Says
From Listening To Advising: The Maturation Of US FDA's Patient-Focused Drug Development Program
FDA's 21st Century Cures Plan Gives Patient-Focused Drug Development A Boost

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC123207

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel